Spotlight on sexually transmitted infections in the West Midlands: 2024 data
Updated 22 April 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/sexually-transmitted-infections-west-midlands-data/spotlight-on-sexually-transmitted-infections-in-the-west-midlands-2024-data
Summary
While this report primarily focuses on the trend between 2023 and 2024, some trends relative to 2019 or earlier are included to provide a comparison to sexual health service provision and STI diagnoses prior to the COVID-19 pandemic during 2020 and 2021. For England, the numbers of consultations, sexual health screens and STI diagnoses in 2020 and 2021 are lower than preceding years and any trends during periods which include those years must be interpreted in that context.
Sexually transmitted infections (STIs) are an important public health issue in the West Midlands. Of the 9 UK Health Security Agency (UKHSA)’s regions, the West Midlands has the fourth lowest rate of new STIs in England.
27,309 new STIs were diagnosed in West Midlands residents in 2024, a rate of 449 diagnoses per 100,000 population. Rates by upper tier local authority ranged from 249 new STI diagnoses per 100,000 population in the County of Herefordshire to 707 per 100,000 population in Wolverhampton.
Overall, the number of new STIs diagnosed in West Midlands residents decreased by 8% between 2023 and 2024. Changes were seen in the numbers of the 5 major STIs: syphilis increased by 14%, gonorrhoea decreased by 19%, chlamydia decreased by 11%, genital herpes increased by 4% and genital warts decreased by 3%.
UKHSA recommends that local areas should be working towards achieving a chlamydia detection rate no lower than 3,250 per 100,000 among women aged 15 to 24 years and this is an indicator in the Public Health Outcomes Framework. In 2024, the chlamydia detection rate among West Midlands women aged 15 to 24 years was 1,290 per 100,000 residents.
Rates of new STIs vary somewhat between men and women (431 and 433 per 100,000 residents, respectively). Where gender and sexual orientation are known, gay, bisexual and other men who have sex with men (GBMSM) account for 16% of West Midlands residents diagnosed with a new STI excluding chlamydia diagnoses reported via CTAD (56% of those diagnosed with syphilis and 38% of those diagnosed with gonorrhoea). STIs disproportionately affect young people. West Midlands residents aged between 15 and 24 years accounted for 39% of all new STI diagnoses in 2024. A steep decline has been seen in genital warts diagnosis rates in females aged 15 to 19 following the introduction in 2008 of vaccination against human papillomavirus (HPV), the virus which causes genital warts, for girls. Recent years have seen fluctuating rates though, with a 47% decrease in West Midlands from 2020 to 2024.
The White ethnic group has the highest number of new STI diagnoses: 15,995 (64.4%). However, 7.9% of new STIs are in the Black Caribbean ethnic group. The Black Caribbean ethnic group have the highest rate of new STI diagnoses: 2,171 per 100,000, which is 6.2 times the rate seen in the White ethnic group.
Where country of birth was known, 82% of West Midlands residents diagnosed with a new STI in 2024 (excluding chlamydia diagnoses reported via CTAD) were UK-born. The rate of new STIs among people who lived in the most deprived areas (664 per 100,000) was 2.6 times higher than the rate for people who live in the least deprived areas (258 per 100,000).
Conclusion
Following the disruption to sexual health services (SHSs) during the COVID-19 pandemic, activity across the West Midlands has continued to recover, with face-to-face and online consultations increasing steadily since 2021. Testing rates, excluding chlamydia screening in under-25s, have risen steadily over the past decade, returning to, and in England surpassing, pre pandemic levels, though positivity rates have remained relatively stable. This suggests that while access to testing has expanded, underlying STI transmission continues, emphasising the importance of sustained investment in SHSs. Chlamydia remains the most commonly diagnosed STI in the West Midlands region, followed by gonorrhoea, which continues to show notable increases among key population groups. Syphilis diagnoses have also risen, particularly among GBMSM, reflecting broader national trends.
Geographic and socioeconomic inequalities persist, with the highest STI rates concentrated in the most deprived areas and in major urban UTLAs such as Wolverhampton, Birmingham, and Stoke-on-Trent.
Marked disparities are also evident by ethnicity, with Black Caribbean and Black African residents experiencing a disproportionately high burden of STIs.
Young people aged 15 to 24 years continue to experience the highest rates of STIs, highlighting the importance of accessible prevention, testing and treatment services for this age group. As online service use grows and consultation patterns evolve, it remains essential to monitor whether changes in service delivery support equitable access across all communities.
Overall, these findings underscore the need for sustained investment and targeted public health interventions for groups most affected by STIs in the West Midlands, in order to reduce STI transmission and address inequalities.
UKHSA’s main messages
Commissioners and providers of Sexual Health Services (SHSs) have an important role in communicating messages about safer sexual behaviours and how to access services.
Main prevention messages include:
- using condoms consistently and correctly protects against HIV and other STIs such as chlamydia, gonorrhoea, and syphilis – condoms can also be used to prevent unplanned pregnancy
- regular screening for STIs and HIV is essential to maintain good sexual health – everyone should have an STI screen, including an HIV test, on at least an annual basis if having condomless sex with new or casual partners
- women, and people with a womb or ovaries, aged under 25 years who are sexually active should have a chlamydia test annually and on change of sexual partner
- gay, bisexual and other men who have sex with men (GBMSM) should have tests for HIV and STIs annually or every 3 months if having condomless sex with new or casual partners
- Doxycycline post-exposure prophylaxis (doxyPEP) is recommended to people at risk of syphilis to reduce their risk of infection – doxyPEP is available at specialist SHSs
- HIV pre-exposure prophylaxis (PrEP) is available for free from specialist SHSs and can be used to reduce an individual’s risk of acquiring HIV
- HIV post-exposure prophylaxis (PEP) can be used to reduce the risk of acquiring HIV following some sexual exposures – PEP is available for free from most specialist SHSs and most emergency departments
- people living with diagnosed HIV who are on treatment and have an undetectable viral load are unable to pass on the infection to others during sex – this is known as ‘Undetectable=Untransmittable’ or ‘U=U’
- vaccination against human papillomavirus (HPV), hepatitis A and hepatitis B will protect against disease caused by these viruses and prevent the spread of these infections
- GBMSM can obtain the hepatitis A and hepatitis B vaccines from specialist SHSs – these vaccines are also available for other people at high risk of exposure to the viruses
- GBMSM aged up to and including 45 years can obtain the HPV vaccine from specialist SHSs
- GBMSM who have a recent history of multiple sexual partners or an STI and other high-risk groups are eligible for a meningococcal B disease vaccine (4CMenB) which can protect against gonorrhoea and help tackle the increasing levels of antibiotic-resistant strains of the disease
- Mpox vaccination is available for those at increased risk, including GBMSM who have a recent history of multiple sexual partners
- Local areas may wish to adopt the STI Prioritisation Framework as it provides a structured, evidence‑informed approach to understanding and responding to local sexual health needs. It supports decision‑making and helps ensure resources are targeted where they will have the most impact.
- specialist SHSs are free and confidential and offer testing and treatment for HIV and STIs, condoms, vaccination, HIV PrEP and PEP
- clinic-based services are commissioned for residents of all areas in England
- online self-sampling for HIV and STIs is widely available
- see information and advice about sexual health including how to access services on NHS.UK and from the national sexual health helpline on 0300 123 7123
Charts, tables, and maps
Figure 1. New STI diagnosis rates by UKHSA region of residence, England, 2024
Data sources: GUMCAD, CTAD
Description of Figure 1
For those residents in the West Midlands, 27,309 new STIs were diagnosed in 2024, a rate of 449 diagnoses per 100,000 population. The West Midlands region had the fourth lowest rate of new STI diagnoses in England in 2024.
Figure 2. Number of diagnoses of the 5 main STIs, West Midlands residents, 2020 to 2024
Data sources: GUMCAD, CTAD
Notes for Figure 2
It is important to consider whether there have been any changes to testing or vaccination practices when interpreting increases or decreases in STIs:
Any increase in gonorrhoea diagnoses may be due to the increased use of highly sensitive nucleic acid amplification tests (NAATs) and additional screening of extra-genital sites in GBMSM. Any decrease in genital wart diagnoses may be due to a moderately protective effect of HPV-16/18 vaccination.
Any increase in genital herpes diagnoses may be due to the use of more sensitive NAATs.
Increases or decreases may also reflect changes in testing practices.
Description of Figure 2
Between 2020 and 2024, chlamydia accounted for the highest number of new diagnoses amongst the 5 main STIs diagnosed in the West Midlands across that period. Genital herpes and syphilis have shown gradual increases across the reporting period. Gonorrhoea diagnoses rose to a peak in 2023 before falling slightly in 2024, while diagnoses of genital warts have shown a gradual decline across the period 2020 to 2024.
Table 1. Percentage change in new STI diagnoses, West Midlands residents
Data sources: GUMCAD, CTAD
| Diagnoses | 2024 | Percentage change 2020 to 2024 | Percentage change 2023 to 2024 |
|---|---|---|---|
| Chlamydia | 13,560 | -2% | -11% |
| Genital Herpes | 1,878 | 23% | 4% |
| Genital Warts | 1,781 | -13% | -3% |
| Gonorrhoea | 5,084 | 27% | -19% |
| Syphilis | 837 | 131% | 14% |
| Other | 4,169 | 40% | 5% |
| All new STIs | 27,309 | 10% | -8% |
Notes for Table 1
See notes for Figure 2. See section on New STIs for a list of diagnoses that are included in the other STIs.
Description of Table 1
Besides the 5 STIs presented above, new diagnoses of other STIs for residents of the West Midlands between 2020 and 2024 have increased by 40%. Overall, new STI diagnoses increased by 10% between 2020 and 2024.
Figure 3. Rates of new STIs per 100,000 West Midlands residents by age group (for those aged 15 to 64 years only) and gender, 2024
Data sources: GUMCAD, CTAD
Description of Figure 3
The rate of new STIs per 100,000 West Midlands residents is the highest in individuals aged 20 to 24, with the rate of new STIs higher amongst females in this age group than in males. Among those aged 24 and under, females have higher rates than males, while in older age groups the pattern reverses.
Figure 4. Rates of gonorrhoea per 100,000 West Midlands residents by age group [note 1] (for those aged 15 to 64 years only), 2020 to 2024
Data sources: GUMCAD
Notes for Figure 4
Note 1: Age-specific rates are shown for those aged 15 to 64 years only.
Description of Figure 4
Gonorrhoea rates increased across most age groups between 2020 and 2022, before declining slightly by 2024 in those age 15 to 19 and 20 to 24. The highest rates across the period 2020 to 2024 are consistently seen among 20 to 24 year olds.
Figure 5. Rates of genital warts per 100,000 West Midlands residents aged 15 to 19 years by gender, 2020 to 2024
Data sources: GUMCAD
Description of Figure 5
Rates of genital warts among 15 to 19-year-olds have steadily declined for both females and males from 2020 to 2024, with females consistently having higher rates than males across the period.
Figure 6. Rates of new STIs per 100,000 West Midlands residents by ethnic group, 2024
Data sources: GUMCAD, CTAD
Description of Figure 6
The rate of new STIs is significantly higher for black Caribbean and black African residents of the West Midlands, compared to other ethnic groups.
Table 2. Percentage of new STI diagnoses among West Midlands residents by ethnic group, 2024
Data sources: GUMCAD, CTAD
| Ethnic group | Number | Percentage (excluding unknown) |
|---|---|---|
| All other ethnic groups combined | 4,856 | 19.6% |
| Black African | 2,013 | 8.1% |
| Black Caribbean | 1,958 | 7.9% |
| White | 15,995 | 64.4% |
| Unknown | 2,487 | - |
The highest number of new STI diagnoses are in white residents of the West Midlands, accounting for 64.4% of the total of those diagnoses where the ethnic group is known.
Figure 7. Percentage of West Midlands residents diagnosed with a new STI by world region of birth [note 1], 2024
Data sources: GUMCAD data only
Notes for Figure 7
Note 1: Data on country of birth is not collected by CTAD. All information about world region of birth is based on diagnoses made in specialist and non-specialist services which report to GUMCAD.
Description of Figure 7
The majority of West Midlands residents diagnosed with a new STI (82%), occur in residents born in the UK, with much smaller proportions born in other regions.
Figure 8. Rates of new STIs per 100,000 West Midlands residents by decile of deprivation [note 1], 2024
Data sources: GUMCAD, CTAD
Notes for Figure 8
Note 1: Deciles run from 1 to 10 in order of decreasing deprivation, with 1 being the decile for the most deprived area.
Description of Figure 8
Rates of new STIs in the West Midlands vary by deprivation decile, with the highest rates of new STIs amongst residents in the most deprived areas and the lowest rates in those who are resident in the least deprived areas.
Figure 9. Diagnoses of the 5 main STIs among GBMSM [note 1], West Midlands residents, 2020 to 2024
Data sources: GUMCAD data only
Notes for Figure 9
Note 1: Data on sexual orientation is not collected by CTAD. All information about GBMSM is based on diagnoses made in specialist and non-specialist services which report to GUMCAD and exclude chlamydia diagnoses via online services.
It is important to consider whether there have been any changes to testing or vaccination practices when interpreting increases or decreases in STIs: Increases in gonorrhoea may be due to the increased use of highly sensitive nucleic acid amplification tests (NAATs) and additional screening of extra-genital sites in GBMSM. Decreases in genital wart diagnoses may be due to the moderately protective effect of HPV-16/18 vaccination. Increases in genital herpes diagnoses may be due to the use of more sensitive NAATs.
Description of Figure 9
Among those who identify as GBMSM in the West Midlands, gonorrhoea and chlamydia remain the most diagnosed STIs across the period 2020 to 2024, with diagnoses of both increasing between 2021 and 2023 before stabilizing in 2024. Genital warts, genital herpes, and syphilis occur at much lower levels across the GBMSM population resident in the West Midlands, with syphilis showing a gradual rise over the period 2020 to 2024.
Table 3. Percentage change in new STI diagnoses in GBMSM [note 1] residents in the West Midlands
Data sources: GUMCAD data only
| Diagnoses | 2023 | 2024 | Percentage change 2023 to 2024 |
|---|---|---|---|
| Chlamydia | 679 | 681 | 0% |
| Genital Herpes | 64 | 67 | 5% |
| Genital Warts | 81 | 69 | -15% |
| Gonorrhoea | 1,404 | 1,366 | -3% |
| Syphilis | 280 | 358 | 28% |
| Other | 253 | 277 | 9% |
| All new STIs | 2,761 | 2,818 | 2% |
Notes for Table 3
See notes for Figure 9 (including Note 1). See New STIs section for a list of diagnoses that are included in the other STIs.
Description of Table 3
Between 2023 and 2024, most STI diagnoses among GBMSM residents in the West Midlands saw small changes, with syphilis increasing the most (28%), and gonorrhoea and genital warts decreasing. Overall, new STI diagnoses rose slightly by 2% amongst the GBMSM residents in the West Midlands.
Figure 10. Rate of new STI diagnoses per 100,000 West Midlands residents by upper tier local authority of residence, 2024
Data sources: GUMCAD, CTAD
Description of Figure 10
Wolverhampton and Stoke-on-Trent had the highest rates of new STI diagnoses in 2024, and the County of Herefordshire the lowest. With the exception of Wolverhampton and Stoke-on-Trent, most UTLAs in the West Midlands recorded a rate of new STI diagnoses in 2024 below that recorded for England (631 per 100,000).
Figure 11. Rate of new STI diagnoses (excluding chlamydia diagnoses in residents aged under 25 years [note 1]) per 100,000 West Midlands residents by upper tier local authority of residence, 2024
Data sources: GUMCAD, CTAD
Notes for Figure 11
Note 1: Chlamydia diagnoses in the target group of the National Chlamydia Screening Programme NCSP (those aged 15 to 24 years) are excluded because these diagnoses could reflect how NCSP is implemented locally rather than actual prevalence.
Description of Figure 11
Excluding chlamydia diagnoses in West Midlands residents age under 25 years, Wolverhampton and Stoke-on-Trent have the highest STI rates in 2024, whilst rates are lowest in Shropshire and Herefordshire upper tier local authorities of residence.
Figure 12. Chlamydia detection rate per 100,000 female West Midlands residents aged 15 to 24 years by upper tier local authority of residence, 2024
Data sources: GUMCAD, CTAD
Description of Figure 12
Wolverhampton, Telford and Wrekin, and Stoke-on-Trent upper tier local authorities recorded the highest chlamydia detection rates amongst female residents aged 15 to 24 years old, all above the average rate for England. Rates were lowest in Warwickshire and Herefordshire, which recorded chlamydia detection rates amongst female residents below those of the regional and national average.
Figure 13. Rate of gonorrhoea diagnoses per 100,000 West Midlands residents by upper tier local authority of residence, 2024
Data sources: GUMCAD
Description of Figure 13
Birmingham, Stoke-on-Trent, and Wolverhampton had the highest rates of gonorrhoea diagnoses amongst upper tier local authorities in the West Midlands in 2024, above the England average. Rates were lowest in Shropshire and Herefordshire.
Figure 14. Map of new STI diagnosis rates per 100,000 West Midlands residents by upper tier local authority, 2024
Data sources: GUMCAD, CTAD
Description of Figure 14
The map above sets out the geographic variation in the rate of new STI diagnoses across West Midlands UTLAs in 2024, with the highest rates concentrated in urban areas including Wolverhampton, Birmingham, and Stoke-on-Trent and lower rates in Herefordshire, Shropshire, and Worcestershire UTLAs.
Figure 15. Map of new STI diagnosis rates per 100,000 West Midlands residents by middle super output area (MSOA21), 2024
Data sources: GUMCAD, CTAD
Description of Figure 15
The map shows variation in new STI diagnosis rates across West Midlands MSOAs in 2024, with a small number of areas exhibiting higher rates being broadly aligned with the UTLAs which recorded the highest new STI diagnosis rates for 2024, including Wolverhampton, Birmingham, and Stoke-on-Trent.
Figure 16. STI testing rate (excluding chlamydia in under 25 year olds [note 1]) per 100,000 West Midlands residents, 2012 to 2024
Data sources: GUMCAD, CTAD
Notes for Figure 16
Note 1: Chlamydia diagnoses in the target group of the National Chlamydia Screening Programme NCSP (those aged 15 to 24 years) are excluded because these diagnoses could reflect how NCSP is implemented locally rather than actual prevalence.
Description of Figure 16
STI testing rates have generally increased in both the West Midlands and nationally for England between 2012 and 2024. A sharp dip occurred in 2020; likely reflecting pandemic-related service disruption, after which testing recovered, though West Midlands rates remain below the national average rate in 2024.
Figure 17. STI testing positivity rate (excluding chlamydia in under 25-year-olds [note 1]) in West Midlands residents, 2012 to 2024
Data sources: GUMCAD, CTAD
Notes for Figure 17
Note 1: Chlamydia diagnoses in the target group of the National Chlamydia Screening Programme NCSP (those aged 15 to 24 years) are excluded because these diagnoses could reflect how NCSP is implemented locally rather than actual prevalence.
Description of Figure 17
In both the West Midlands and for England as a whole, STI testing positivity rates (excluding chlamydia in under 25 year olds) have shown a slight increase between 2012 and 2024. By 2024, positivity had declined slightly compared the previous 2 years, with the STI testing positivity rate for England at 6.4% and for the West Midlands at 6.2%. The West Midlands regional STI positivity rate and the rate for England are similar across the period 2012 to 2024.
Table 4. Number of diagnoses of new STIs by UKHSA region of residence, data source and data subset 2024
Data sources: GUMCAD, CTAD
| UKHSA region of residence | GUMCAD specialist SHSs |
GUMCAD non-specialist SHSs [note 1] |
CTAD [note 2] | Total |
|---|---|---|---|---|
| East Midlands | 13,865 | 5,900 | 4,244 | 24,009 |
| East of England | 17,674 | 2,317 | 6,551 | 26,542 |
| London | 87,381 | 11,044 | 23,995 | 122,420 |
| North East | 10,121 | 1,722 | 3,004 | 14,847 |
| North West | 33,672 | 4,248 | 9,175 | 47,095 |
| South East | 29,777 | 2,455 | 8,472 | 40,704 |
| South West | 17,434 | 2,856 | 4,797 | 25,087 |
| West Midlands | 19,125 | 4,566 | 3,618 | 27,309 |
| Yorkshire and Humber | 20,263 | 1,671 | 6,339 | 28,273 |
| UK (not England or Wales) | - | - | 3 | 3 |
Notes for Table 4
Note 1: Diagnoses from enhanced GPs reporting to GUMCAD are included in the ‘Non-specialist sexual health services (SHSs)’ total.
Note 2: Including site type 12 chlamydia from GUMCAD.
Description of Table 4
Of the 9 UKHSA regions of residence, the West Midlands was the region with the fifth highest number of new STI diagnoses in 2024 (n=27,309). In all regions, the majority of new STIs were diagnosed in specialist SHSs.
Table 5. Number of diagnoses of the 5 main STIs in the West Midlands by STI, data source and data subset 2024
Data sources: GUMCAD, CTAD
| 5 main STIs | GUMCAD specialist SHSs |
GUMCAD non-specialist SHSs [note 1] |
CTAD [note 2] | Total |
|---|---|---|---|---|
| Chlamydia | 6,884 | 3,058 | 3,618 | 13,560 |
| Genital Herpes | 1,877 | 1 | - | 1,878 |
| Genital Warts | 1,780 | 1 | - | 1,781 |
| Gonorrhoea | 3,858 | 1,226 | - | 5,084 |
| Syphilis | 837 | 0 | - | 837 |
Notes for Table 5
Note 1: Diagnoses from enhanced GPs reporting to GUMCAD are included in the ‘Non-specialist sexual health services (SHSs)’ total.
Note 2: Including site type 12 chlamydia from GUMCAD.
Description of Table 5
In the West Midlands for 2024 the majority of all 5 main STIs were diagnosed in specialists SHSs, with chlamydia and gonorrhoea being the most frequently diagnosed.
Figure 18. Consultations by service medium: West Midlands residents, 2020 to 2024
Data sources: GUMCAD
Description of Figure 18
Between 2020 and 2024 online consultations in the West Midlands have increased, with face-to-face consultations remaining broadly stable across this period. Telephone consultations declined after a peak in 2022 reflecting a shift back toward in-person and digital service use following pandemic related disruptions.
Information on data sources
Find more information on local sexual health data sources in the UKHSA guide.
The gender and age group chart are restricted to those aged 15 to 64 years as information about STIs in those aged under 15 years is considered highly sensitive. Analyses specific to this group are not provided in routine outputs. Rates for those aged 65 or older are withheld to ensure that no deductive disclosure is possible for the under 15 years age group. The proportion of STIs in those aged under 15 years or older than 64 years is very low.
GUMCAD surveillance system
This disaggregates reporting system collects information about attendances and diagnoses at specialist (Level 3) and non-specialist (Level 2) sexual health services. Information about the patient’s area of residence is collected along with demographic data and other variables. GUMCAD superseded the earlier KC60 system and can provide data from 2009 onwards. GUMCAD is the main source of data for this report.
Due to limits on how much personally identifiable information sexual health clinics are able to share, it is not possible to deduplicate between different clinics. There is a possibility that some patients may be counted more than once if they are diagnosed with the same infection (for infection specific analyses) or a new STI of any type (for new STI analyses) at different clinics during the same calendar year.
CTAD surveillance system
CTAD collects data on all NHS and local authority, or NHS-commissioned chlamydia testing carried out in England. CTAD is comprised of all chlamydia (NAATs) tests for all ages (with the exception of conjunctival samples), from all venues and for all reasons. CTAD enables unified, comprehensive reporting of all chlamydia data, to effectively monitor the impact of the NCSP through estimation of the coverage of population screening, proportion of all tests that are positive and detection rates.
For services which report to GUMCAD and for which CTAD does not receive data on the patient’s area of residence (for example, SHSs), information about chlamydia diagnoses is sourced from GUMCAD data.
CTAD does not collect information about sexual orientation or country of birth. Reports from CTAD are excluded from figures in this report which relate to analyses by sexual orientation or world region of birth.
New STIs
New STI diagnoses comprise diagnoses of the following: chancroid, LGV, donovanosis, chlamydia, gonorrhoea, genital herpes (first episode), HIV (acute and AIDS defining), Molluscum contagiosum, non-specific genital infection (NSGI), non-specific pelvic inflammatory disease (PID) and epididymitis, chlamydial PID and epididymitis (presented in chlamydia total), gonococcal PID and epididymitis (presented in gonorrhoea total), scabies, pediculosis pubis, syphilis (primary, secondary and early latent), trichomoniasis and genital warts (first episode), Mycoplasma genitalium, shigella.
###Calculations
Confidence Intervals were calculated using Byar’s method for numerators greater than or equal to 10. For small numerators Byar’s method is less accurate and so an exact method based on the Poisson distribution is used.
ONS mid-year population estimates for 2023 were used as a denominator for rates (other than by ethnic group) for 2024. ONS estimates of population by ethnic group for the year 2019 were used as a denominator for rates by ethnic group for 2024. This is the first time that new estimates of population by ethnic group have been available since 2011. This must be considered if comparing rates for 2024 in this report with rates by 2023 in last year’s report, as the rates in the last report used the 2011 estimates.
Further information
As of 2020, all analyses for this report include data from non-specialist (Level 2) SHSs and enhanced GP services as well as specialist (Level 3) SHSs.
For further information, access the online Sexual and Reproductive Health Profiles.
For more information on HIV data, see the separate HIV Spotlight report.
For more information on local sexual health data sources, see the UKHSA guide.
Local authorities have access to The Summary Profile of Local Authority Sexual Health (SPLASH) Reports (accessible from the Sexual and Reproductive Health Profiles) and the SPLASH supplement reports via the HIV and STI Data exchange.
About the Field Services
The Field Services was established in 2018 as a national service comprising geographically dispersed multi-disciplinary teams integrating expertise in Field Epidemiology, Real-time Syndromic Surveillance and Public Health Microbiology to strengthen the surveillance, intelligence and response functions of UKHSA.
You can contact your local FS team at FSMidlands@ukhsa.gov.uk.
Acknowledgements
We would like to thank the following:
- local SHSs for supplying the SHS data
- local laboratories for supplying the CTAD data
- UKHSA Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Division for collection, analysis and distribution of data